Kalil A C, Dakroub H, Freifeld A G
Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE 68198-5400, USA.
Curr Drug Targets. 2007 Apr;8(4):533-41. doi: 10.2174/138945007780362746.
Approximately seventy patients undergo solid organ transplantation (SOT) every day in the United States. Sepsis remains the first or second most common cause of death in transplant recipients, depending on the allograft type. The rapid diagnosis and treatment of sepsis is critical to ensure improved survival outcome in this special patient population. However, these patients frequently lack the classic systemic inflammatory response syndrome (SIRS), commonly seen in the immunocompetent patients. In order to minimize delays in the diagnosis of sepsis in SOT recipients, it is paramount to recognize the specific risk factors for infection associated with each allograft type. In addition, the particular surgical techniques involved in each type of transplantation may be closely related to the clinical manifestations of the infection process. This correlation can further advance the diagnosis and treatment of sepsis. In conclusion, precocious diagnosis, rapid initiation of antibiotics, surgical correction when necessary, and reduction of immunosuppression, are the mainstream approach to sepsis in the SOT patient. The recent developments in severe sepsis are discussed in the context of the transplant recipient.
在美国,每天约有70名患者接受实体器官移植(SOT)。根据移植器官类型的不同,脓毒症仍是移植受者死亡的首要或第二大常见原因。脓毒症的快速诊断和治疗对于确保这一特殊患者群体的生存结局改善至关重要。然而,这些患者常常缺乏免疫功能正常患者中常见的典型全身炎症反应综合征(SIRS)。为尽量减少SOT受者脓毒症诊断的延迟,认识与每种移植器官类型相关的特定感染危险因素至关重要。此外,每种移植类型所涉及的特定手术技术可能与感染过程的临床表现密切相关。这种相关性可进一步推动脓毒症的诊断和治疗。总之,早期诊断、迅速开始使用抗生素、必要时进行手术矫正以及降低免疫抑制,是SOT患者脓毒症的主流治疗方法。本文在移植受者的背景下讨论了严重脓毒症的最新进展。